News & Analysis on Clinical Trial Services & Contract Research And Development
Royal DSM NV has confirmed that Percivia – its biosimilars joint venture (JV) with Crucell - is to cease in-house product development after failing to agree on future investment and says that job losses are likely.
Acquisition of rival RDDT gave vivoPharm a larger share of Australia’s toxicity services market and will reduce outsourcing costs, says CEO.
The FDA sent 40 per cent more GMP warning letters to biopharma facilities outside the US in fiscal 2011 than the previous year.
E.coli can be used as a cheaper and quicker way to make industrial quantities of “human-like” glycoproteins, according to new research.
Quintiles’ decision to hire Accenture’s Tom Pike as its new CEO suggests consulting services will be even more important in the future for the world’s largest CRO.
Merck Serono has spared its Swiss manufacturing facilities from the most severe of its cuts but will reduce headcount.
Icon posted double-digit year-on-year sales growth and an uptick, excluding one-off charges, in operating income.
Novartis is outsourcing to CMOs to keep up supply of certain products while it fixes problems at its Nebraska plant.
In-Pharmatechnologist.com has chosen Interphex - the drug industry’s biggest production and processing technology show – as the launch event for our new look, refocused news website.